08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
In this episode of Excellence in Training, Shawn Rogers and I consider the establishing of your comp...
Read More >
The Department of Labor just published its increases to the maximum civil penalties that can be asse...
Read More >
Dear Friend, Wow, have I missed you. Sure, I’ve seen you around but YOU are not the YOU I know. He...
Read More >
The COVID-19 pandemic is having a profound impact on construction projects across Canada causing del...
Read More >
As esports have remained resilient during the pandemic, investors have shown a commitment to levelin...
Read More >
The new state law reflects a trend among other states including New Hampshire, Maine, Maryland, Oreg...
Read More >